Mild Therapeutic Hypothermia (TH) is defined as a temperature range of 32-35°C. Temperatures in this range protect both cardiac and neural cells from the damage of ischemia and reperfusion by slowing metabolic rates, reducing oxygen requirements, and suppressing capillary obstruction caused by inflammation. As a result, TH may be a ground-breaking adjunct to reperfusion therapy in many patient conditions, including heart attacks, ischemic stroke, and cardiac arrest.
Therapeutic Hypothermia may be applicable in multiple markets totaling $2B+ in revenue potential. Velomedix is currently focused on acute myocardial infarction applications (i.e. heart attacks) but expects to target cardiac arrest, stroke, and traumatic brain injury in the near future, directly or through strategic partnerships.